Post by Lonza

What if CAR-T therapy could be delivered without leukapheresis, individualized manufacturing, or weeks of waiting? That vision is driving unprecedented momentum behind in vivo CAR-T, one of the most closely watched areas in cell and gene therapy today. With major investments from leading biopharma companies and multiple clinical programs now underway, the conversation has shifted beyond whether in vivo CAR-T can work to how developers can successfully deliver, manufacture, scale, and regulate these therapies. Our new white paper examines: • Emerging market and investment trends • Viral vs. non-viral delivery strategies • Critical manufacturing challenges and opportunities • The evolving role of CDMO partners in accelerating development As innovation continues to advance, manufacturing excellence may become just as important as biological innovation. Download the white paper and explore the future of in vivo CAR-T. https://lnkd.in/ey36_n5p #InvivoCART #CellAndGeneTherapy #Biotech #Biopharma #CGT #AdvancedTherapies #CDMO #mRNA #LentiviralVectors #Lonza